Description

This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) provides technological insights across 26 global healthcare innovations. The technologies analyzed include advances in digital health, biologics, small molecules, medical imaging, dental caries and precision oncology platforms. The TOE also covers application and megatrends impact, apart from exclusive analyst insights for each innovation.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Capsule Technologies, Health-IT, data management, GenXComm, Dell Technologies, digital pathology, BlueBee, Multiomics, Numares Health, precision oncology, Entasis Therapeutics Holdings Inc., Antibiotic Resistance, CALCiViS Ltd., dental caries, non-invasive diagnostics, Congenica Ltd., Genomics, Previvo Genetics LLC, non-invasive reproductive technology, Gedea Biotech AB, infectious diseases, pHyph, drug resistance, LabGenius Ltd., protein therapeutics, machine learning, Nanoform Finland Oy, drug solubility, OSSIO Inc., orthopedic surgery, bone healing, Protalix Biotherapeutics Inc., protein production, Novo Nordisk, oral glucagon-like peptide-1 (GLP-1) receptor agonist, Locus Biosciences, CRSIPR, Phage, NanoString Technologies, Inc., organ transplantation, bioMérieux, renal care, cardiac surgery, ReNeuron, stem cell therapy, Stealth BioTherapeutics, mitochondrial disease, Elamipretide, Akcea Therapeutics, liver protein, Boston Pharmaceuticals, triple-negative breast cancer, Arcellx, adaptive immune therapies, Reata Pharmaceuticals, small molecule, Friedrich’s Ataxia, Stanford University, neuron regeneration, Ziopharm Oncology, gene therapy